Quince Therapeutics Inc. is scrapping work with dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP) for patients with ataxia-telangiectasia (A-T), and Boral analyst Jason Kolbert said “the core value driver has been effectively removed, and the equity appears fully impaired at this stage.” Read More
The EMA has started a review of Amgen Inc.’s Tavneos (avacopan) after questions were raised about the integrity of the data in the Advocate study that the agency assessed when granting approval of the vasculitis treatment in January 2022. Read More
Astrazeneca plc is investing $15 billion in China through 2030 to expand R&D and manufacturing, marking one of the largest long-term investments by a multinational pharma company in the country. The U.K.-based company also struck a deal worth up to $3.5 billion with China’s CSPC Pharmaceuticals Group Ltd. to accelerate the development of next-generation therapies for obesity and type 2 diabetes. Read More
Elevar Therapeutics Inc. appointed Kim Dong-gun (DG) as CEO Jan. 29, as the company focuses on post-NDA strategies for lirafugratinib in bile duct cancer, and the twice-rejected rivoceranib-camrelizumab combination for liver cancer. Read More
Beginning Feb. 2, 2026, medical technology news and analysis will be integrated into BioWorld, where curated coverage will continue as part of BioWorld’s core reporting.
This transition reflects how innovation across the life sciences is increasingly interconnected. By featuring med-tech coverage within BioWorld, readers gain a more complete perspective of key developments in medical technologies alongside therapeutics all in one place.
The final edition of BioWorld MedTech will publish on Jan. 30, 2026, introducing a more streamlined and comprehensive experience for readers starting on Monday, Feb. 2, 2026.
All existing BioWorld MedTech subscribers will be automatically transitioned to BioWorld Premium, ensuring continued access to med-tech coverage as part of a broader view of research, clinical development and commercialization.
As BioWorld continues its mission to cut through the noise of the life sciences industry with accuracy, clarity and context, this integration ensures readers are well-positioned to track the connections shaping innovation across the global life sciences ecosystem.
Thank you for being part of the BioWorld MedTech community. We invite you to continue following coverage within BioWorld.
After reaching their peaks in late November, both the BioWorld Drug Developers Index and the Nasdaq Biotechnology Index finished the year slightly down from those highs. Read More
Chemotherapy is often seen solely as a tumor-targeting treatment, yet new evidence reveals a paradox: the tissue injury it causes can reprogram the body’s defenses, influencing the risk of metastasis. Researchers from the University of Lausanne and collaborators reported that chemotherapy reshapes the gut-immune axis by inducing microbiota-derived indole-3-propionic acid, which reprograms myelopoiesis to curb monocyte-driven immunosuppression and metastasis in colorectal cancer. Read More
Biopharma happenings, including deals and partnerships, and other news in brief: Alvotech, Bayer, Chia Tai Feng Hai, Formation Bio, Regeneron, Repare, Xeno. Read More
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Almirall, Elevar, Summit, Tenpoint. Read More
-CEO-Elevar-1-30.webp?t=1769801176 "Kim Dong-gun (DG), CEO, Elevar")
